Iborra, M; Botella, B; Martin-Arranz, M-D; Ceballos, D; Martínez-Pascual, C; Garrido, A; Varela, P; Moreta, M; Brunet-Mas, Eduard; González-Lama, Y; Rodríguez-González, E; Vicuna, M; Gisbert, J-P; Ordas, I; Arguelles-Arias, F; Tosca-Cuquerella, J; Vicente-Lidon, R; Sierra-Ausin, M; Rodríguez-Lago, I; Martin-Rodríguez, D; Paredes, JM; Sicilia, B; García-de-la-Filia, I; Jiménez, N; Barreiro-de-Acosta, M; Betore, E; Ferrer-Bradley, I; García-Alles, L; Huguet, JM; Castellet-Farrus, S; García, M-J; Gutiérrez-Casbas, A; Ponferrada-Díaz, A; Ramos, L; Calafat, M; Vera, I; Suárez-Ferrer, Consuelo; Fernández-Velado, E; Rodríguez-Sánchez, S; Mínguez, A; Mancebo, A; Barrio, J; Lario, S; de-La-Cruz, D-R; Hernández-Camba, Alejandro; Rodríguez-Gutiérrez, C; Chaparro, M; Ricart, E; Almenara-Michelena, L; Balaguer, A; Domenech, E; Nos, P
(WILEY, 2026-05)
BACKGROUND: Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real-world data, particularly from large nationwide cohorts, remain limited. This study aimed ...